Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$1.91 -2.6%	$2.00	$1.12 ▼ $4.20	$141.99M	0.94	238,374 shs	58,585 shs
KYTX Kyverna Therapeutics	$3.46 +4.5%	$2.30	$1.78 ▼ $16.64	$149.54M	2.52	418,437 shs	388,003 shs
LUMO Lumos Pharma	$4.34	$4.34	$1.37 ▼ $4.58	$37.54M	0.74	85,612 shs	N/A
LXEO Lexeo Therapeutics	$4.09 -9.3%	$3.08	$1.45 ▼ $19.50	$135.78M	0.52	522,404 shs	531,587 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	-2.24%	-1.01%	-10.50%	-10.91%	+22.88%
KYTX Kyverna Therapeutics	-8.06%	+16.14%	+49.77%	+32.40%	-74.67%
LUMO Lumos Pharma	0.00%	0.00%	0.00%	0.00%	+70.20%
LXEO Lexeo Therapeutics	-2.17%	+45.48%	+71.48%	+51.85%	-74.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IKT Inhibikase Therapeutics	1.4971 of 5 stars	3.3	1.0	0.0	0.0	2.6	0.0	0.6
KYTX Kyverna Therapeutics	2.2233 of 5 stars	3.6	3.0	0.0	0.0	2.0	1.7	0.0
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	3.8101 of 5 stars	4.6	2.0	0.0	0.0	2.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	240.31% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	434.68% Upside
LUMO Lumos Pharma	3.00	Buy	$8.63	98.73% Upside
LXEO Lexeo Therapeutics	3.14	Buy	$18.50	352.32% Upside

Current Analyst Ratings Breakdown

Latest LUMO, KYTX, LXEO, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKT Inhibikase Therapeutics	$260K	546.13	N/A	N/A	$1.78 per share	1.07
KYTX Kyverna Therapeutics	$7.03M	21.27	N/A	N/A	N/A	∞
LUMO Lumos Pharma	$2.21M	17.02	N/A	N/A	$3.45 per share	1.26
LXEO Lexeo Therapeutics	$650K	208.89	N/A	N/A	$4.26 per share	0.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
LUMO Lumos Pharma	-$34.03M	-$4.29	N/A	N/A	N/A	-1,583.49%	-233.03%	-129.88%	N/A
LXEO Lexeo Therapeutics	-$66.39M	-$3.30	N/A	N/A	N/A	N/A	-57.66%	-48.18%	8/11/2025 (Estimated)

Latest LUMO, KYTX, LXEO, and IKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKT Inhibikase Therapeutics	N/A	0.85	0.85
KYTX Kyverna Therapeutics	N/A	10.50	10.50
LUMO Lumos Pharma	N/A	2.66	2.66
LXEO Lexeo Therapeutics	0.01	5.95	5.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKT Inhibikase Therapeutics	3.81%
KYTX Kyverna Therapeutics	18.08%
LUMO Lumos Pharma	33.99%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
IKT Inhibikase Therapeutics	7.30%
KYTX Kyverna Therapeutics	22.00%
LUMO Lumos Pharma	25.40%
LXEO Lexeo Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
LUMO Lumos Pharma	30	8.65 million	6.45 million	Not Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.58 million	Not Optionable

LUMO, KYTX, LXEO, and IKT Headlines

Recent News About These Companies

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC

June 6, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Price Target Lowered to $10.00 at JPMorgan Chase & Co.

May 31, 2025 | marketbeat.com

Leerink Partnrs Issues Positive Forecast for LXEO Earnings

May 31, 2025 | marketbeat.com

Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares

May 29, 2025 | nasdaq.com

Lexeo raises $80 million to shore up gene therapy work after layoffs

May 28, 2025 | thepharmaletter.com

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 27, 2025 | globenewswire.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of "Buy" by Brokerages

May 24, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Trims Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 23, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Holdings Lifted by Point72 Asset Management L.P.

May 22, 2025 | marketbeat.com

Vestal Point Capital LP Raises Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for LXEO Issued By HC Wainwright

May 21, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Holdings Lifted by Janus Henderson Group PLC

May 17, 2025 | marketbeat.com

Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating

May 16, 2025 | tipranks.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Down 5.61%

May 15, 2025 | aaii.com

Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

May 15, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Omega Fund Management LLC

May 15, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Misses Expectations By $0.19 EPS

May 14, 2025 | marketbeat.com

Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies

May 12, 2025 | fiercebiotech.com

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 12, 2025 | globenewswire.com

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

May 5, 2025 | seekingalpha.com

Why Lexeo Therapeutics, Inc.’s (LXEO) Stock Is Up 9.41%

May 2, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUMO, KYTX, LXEO, and IKT Company Descriptions

Inhibikase Therapeutics NYSE:IKT

$1.91 -0.05 (-2.55%)

As of 04:00 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Kyverna Therapeutics NASDAQ:KYTX

$3.46 +0.15 (+4.53%)

As of 04:00 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Lumos Pharma NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Lexeo Therapeutics NASDAQ:LXEO

$4.09 -0.42 (-9.31%)

As of 04:00 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time